Immatics/$IMTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Immatics
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
- Ticker
- $IMTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 704
- Headquarters
- Tübingen, Germany
- Website
- www.immatics.com
Immatics Metrics
BasicAdvanced
$914M
-
-$1.88
-
-
Price and volume
Market cap
$914M
52-week high
$12.41
52-week low
$6.09
Average daily volume
1.1M
Financial strength
Current ratio
5.025
Quick ratio
2.871
Long term debt to equity
0.026
Total debt to equity
0.032
Profitability
EBITDA (TTM)
-268.228
Gross margin (TTM)
-323.19%
Net profit margin (TTM)
-534.13%
Operating margin (TTM)
-577.09%
Effective tax rate (TTM)
0.21%
Revenue per employee (TTM)
$66,460
Management effectiveness
Return on assets (TTM)
-28.90%
Return on equity (TTM)
-54.26%
Valuation
Price to revenue (TTM)
19.038
Price to book
2.32
Price to tangible book (TTM)
2.33
Price to free cash flow (TTM)
-3.67
Free cash flow yield (TTM)
-27.25%
Free cash flow per share (TTM)
-1.823
Growth
Revenue change (TTM)
-48.75%
Earnings per share change (TTM)
71.01%
3-year revenue growth (CAGR)
-16.91%
3-year earnings per share growth (CAGR)
16.37%
What the Analysts think about Immatics
Analyst ratings (Buy, Hold, Sell) for Immatics stock.
Analyst projections of the future price of Immatics stock.
Bulls say / Bears say
Anzu-cel showed a 56% confirmed response rate in Phase 1b melanoma data, with a median response duration of 14.6 months. That offers encouraging clinical evidence ahead of the pivotal Phase 3 readout. (GlobeNewswire)
The broader pipeline has shown activity beyond melanoma: IMA203CD8 reported a 63% response rate in a small group of patients with hard-to-treat gynaecological cancers, while IMA401 showed responses in several solid tumours. This gives Immatics additional clinical opportunities if early findings hold up in larger studies. (Immatics N.V., Nature Medicine)
Immatics reported $448.2 million in cash and other financial assets at the end of June and projected a cash reach into 2028. That provides a substantial funding buffer for development and the expected Phase 3 readout. (GlobeNewswire)
The pivotal SUPRAME trial is accumulating progression-free-survival events more slowly than expected. Immatics dropped its planned interim analysis and now expects final Phase 3 data in the first half of 2027, leaving investors without a near-term efficacy checkpoint. (SEC)
Evidence for IMA401 is still early and uneven: the Phase 1 study reported a 14% confirmed response rate across all dose levels, and the largest reported tumour subgroup had only 14 patients. Grade 3 or higher treatment-related adverse events occurred in 51% of participants, underscoring efficacy and safety risks as the programme advances. (Nature Medicine)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
Immatics Financial Performance
Revenues and expenses
Immatics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.